Literature DB >> 19561632

ASCT in follicular lymphoma.

Jennifer R Brown, Arnold S Freedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19561632     DOI： 10.1038/nrclinonc.2009.87

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Authors:  Catherine Sebban; Nicolas Mounier; Nicole Brousse; Coralie Belanger; Pauline Brice; Corinne Haioun; Herve Tilly; Pierre Feugier; Redah Bouabdallah; Chantal Doyen; Gilles Salles; Bertrand Coiffier
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

2.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

Authors:  Eric Deconinck; Charles Foussard; Noel Milpied; Philippe Bertrand; Patrick Michenet; Pascale Cornillet-LeFebvre; Martine Escoffre-Barbe; Herve Maisonneuve; Vincent Delwail; Remy Gressin; Eric Legouffe; Jean-Pierre Vilque; Bernard Desablens; Jerome Jaubert; Jean-François Ramee; Arash Jenabian; Antoine Thyss; Annick Le Pourhiet-Le Mevel; Philippe Travade; Roselyne Delepine; Philippe Colombat
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

3.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

Authors:  Harry C Schouten; Wendi Qian; Stein Kvaloy; Adolfo Porcellini; Hans Hagberg; Hans Erik Johnsen; Jeanette K Doorduijn; Matthew R Sydes; Gunnar Kvalheim
Journal:  J Clin Oncol       Date:  2003-09-29       Impact factor: 44.544

4.  High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

Authors:  Emmanuel Gyan; Charles Foussard; Philippe Bertrand; Patrick Michenet; Steven Le Gouill; Christian Berthou; Hervé Maisonneuve; Vincent Delwail; Rémi Gressin; Philippe Quittet; Jean-Pierre Vilque; Bernard Desablens; Jérôme Jaubert; Jean-François Ramée; Nina Arakelyan; Antoine Thyss; Cécile Moluçon-Chabrot; Roselyne Delépine; Noël Milpied; Philippe Colombat; Eric Deconinck
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

5.  Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Authors:  Jennifer R Brown; Heather Yeckes; Jonathan W Friedberg; Donna Neuberg; Helen Kim; Lee M Nadler; Arnold S Freedman
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

6.  Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.

Authors:  Marco Ladetto; Federica De Marco; Fabio Benedetti; Umberto Vitolo; Caterina Patti; Alessandro Rambaldi; Alessandro Pulsoni; Maurizio Musso; Anna M Liberati; Attilio Olivieri; Andrea Gallamini; Enrico Pogliani; Delia Rota Scalabrini; Vincenzo Callea; Francesco Di Raimondo; Vincenzo Pavone; Alessandra Tucci; Sergio Cortelazzo; Alessandro Levis; Mario Boccadoro; Ignazio Majolino; Alessandro Pileri; Alessandro M Gianni; Roberto Passera; Paolo Corradini; Corrado Tarella
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

7.  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

Authors:  Georg Lenz; Martin Dreyling; Eva Schiegnitz; Roswitha Forstpointner; Hannes Wandt; Mathias Freund; Georg Hess; Lorenz Truemper; Volker Diehl; Martin Kropff; Michael Kneba; Norbert Schmitz; Bernd Metzner; Markus Pfirrmann; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

8.  Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

Authors:  Ama Z S Rohatiner; Lee Nadler; Andrew J Davies; John Apostolidis; Donna Neuberg; Janet Matthews; John G Gribben; Peter M Mauch; T Andrew Lister; Arnold S Freedman
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544

9.  Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

Authors:  Jennifer R Brown; Yang Feng; John G Gribben; Donna Neuberg; David C Fisher; Peter Mauch; Lee M Nadler; Arnold S Freedman
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

10.  Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

Authors:  Catherine Sebban; Pauline Brice; Richard Delarue; Corinne Haioun; Bertrand Souleau; Nicolas Mounier; Nicole Brousse; Pierre Feugier; Hervé Tilly; Philippe Solal-Céligny; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.